TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 95 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $28,000 | -58.8% | 25,055 | +2.3% | 0.00% | – |
| Q3 2018 | $68,000 | -19.0% | 24,500 | +4.3% | 0.00% | – |
| Q2 2018 | $84,000 | +21.7% | 23,500 | +4.4% | 0.00% | – |
| Q1 2018 | $69,000 | -51.4% | 22,500 | 0.0% | 0.00% | – |
| Q4 2017 | $142,000 | -7.8% | 22,500 | 0.0% | 0.00% | – |
| Q3 2017 | $154,000 | -4.9% | 22,500 | -1.3% | 0.00% | – |
| Q2 2017 | $162,000 | -93.9% | 22,800 | -59.3% | 0.00% | -100.0% |
| Q2 2015 | $2,656,000 | +129.2% | 55,967 | +76.9% | 0.00% | +100.0% |
| Q1 2015 | $1,159,000 | -49.9% | 31,631 | -45.8% | 0.00% | 0.0% |
| Q4 2014 | $2,315,000 | +66.7% | 58,307 | -16.3% | 0.00% | 0.0% |
| Q3 2014 | $1,389,000 | – | 69,626 | +231986.7% | 0.00% | – |
| Q2 2014 | $0 | -100.0% | 30 | -95.8% | 0.00% | – |
| Q3 2013 | $8,000 | +60.0% | 718 | 0.0% | 0.00% | – |
| Q2 2013 | $5,000 | – | 718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 354,300 | $7,068,000 | 2.77% |
| Opaleye Management Inc. | 169,700 | $3,385,515,000 | 2.64% |
| Broadfin Capital, LLC | 959,247 | $19,137,000 | 2.01% |
| Novo Holdings A/S | 900,000 | $17,955,000 | 1.75% |
| Eventide Asset Management | 300,900 | $6,003,000 | 0.84% |
| EAM Investors, LLC | 152,595 | $3,044,000 | 0.62% |
| COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT | 497,858 | $9,932,000 | 0.51% |
| Granite Point Capital Management, L.P. | 40,000 | $798,000 | 0.40% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,191 | $8,981,000 | 0.33% |
| TFS CAPITAL LLC | 133,070 | $2,655,000 | 0.23% |